Amgen Axes Partnership with TScan Therapeutics Amid Cancer Therapy Development

Amgen is terminating its partnership with TScan Therapeutics, ending their collaboration on an immunotherapy treatment. The news was announced in a brief update by Endpoints News. This move follows a series of recent developments in the biotech sector.

TScan Therapeutics has been working with Amgen to develop a potential cancer therapy based on its T-cell scanning technology. However, it seems that the partnership did not yield the desired results for both parties involved.

Amgen is not commenting further on the reasons behind this decision. It's worth noting that partnerships like these often involve significant investments and are typically subject to various conditions and milestones.